Rondanelli, Mariangela
Minisola, Salvatore
Barale, Marco
Barbaro, Daniele
Mansueto, Francesca
Battaglia, Santina
Bonaccorsi, Gloria
Caliri, Santina
Cavioni, Alessandro
Colangelo, Luciano
Corbetta, Sabrina
Coretti, Federica
Dito, Giorgia
Gavioli, Valentina
Ghigo, Ezio
Giannattasio, Raffaele
Lapi, Paola
Maiorana, Blas
Marra, Costanza
Mazzantini, Maurizio
Morini, Elisabetta
Nannipieri, Fabrizio
Nuzzo, Vincenzo
Parri, Fabiana
Perna, Simone
Santori, Rachele
Procopio, Massimo
Funding for this research was provided by:
Abiogen Pharma SpA, Pisa, Italy
Università degli Studi di Pavia
Article History
Received: 22 November 2023
Accepted: 3 January 2024
First Online: 12 February 2024
Declarations
:
: MR received consultancy fees from Abiogen Pharma; SM served as speaker for Abiogen Pharma, Bruno Farmaceutici, Diasorin, Geopharma, Sandoz, UCB and he also served on the advisory board for Abiogen Pharma, Eli Lilly, Kyowa Kirin, Novo Nordisk, UCB; GB received research grant to Institution from Abiogen Pharma and Savio Pharma; MB participated in advisory board for Sandoz; SB and FN are employees of Abiogen Pharma. SC2 received Institution research grant from Sandoz and Gedeon Richter; CM has non-conditional relationship with Abiogen Pharma; RG has a non-conditional relationship with IBSA Farmaceutici Italia, Bruno Farmaceutici, Abiogen Pharma, Amgen, Savio Pharma Italia; All remaining authors declare no conflict of interest.
: This study was approved by the Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (approval number N. 20180107341) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.
: Written informed consent for participation in the study (signed and dated by the interested party).